肝移植中原发性胆汁性肝硬化的复发：免疫抑制的影响。
Recurrence of primary biliary cirrhosis in the liver allograft: the effect of immunosuppression.
作者信息
Dmitrewski J, Hubscher S G, Mayer A D, Neuberger J M
机构信息
Liver Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK.
出版信息
J Hepatol. 1996 Mar;24(3):253-7. doi: 10.1016/s0168-8278(96)80001-8.
BACKGROUND
Recurrence of primary biliary cirrhosis in the liver allograft remains controversial.
METHODS
We have examined the liver allograft biopsies taken at 1 and 2 years after transplantation from patients receiving either FK506 or cyclosporin as part of a multi-centre trial.
RESULTS
Histological features characteristic for primary biliary cirrhosis, including bile duct damage, ductopenia, bile duct proliferation and portal granulomas, were found more commonly and earlier after transplantation in patients receiving FK506 than cyclosporin. During the 2-year period, seven of 16 patients receiving FK506 and only one of 11 on cyclosporin had a graft biopsy suggestive of recurrent primary biliary cirrhosis.
CONCLUSIONS
These findings confirm earlier reports that features of primary biliary cirrhosis recur in the liver allograft in some patients and suggest that the rate of recurrence may be affected by the immunosuppression regimen used.
背景
肝移植中原发性胆汁性肝硬化的复发仍存在争议。
方法
在一项多中心试验中，我们检查了接受FK506或环孢素治疗的患者在移植后1年和2年时所取的肝移植活检标本。
结果
与接受环孢素治疗的患者相比，接受FK506治疗的患者在移植后更常见且更早出现原发性胆汁性肝硬化的组织学特征，包括胆管损伤、胆管减少、胆管增生和门脉肉芽肿。在2年期间，接受FK506治疗的16例患者中有7例，而接受环孢素治疗的11例患者中仅有1例的移植活检提示原发性胆汁性肝硬化复发。
结论
这些发现证实了早期的报道，即部分患者的肝移植中会出现原发性胆汁性肝硬化的特征，并提示复发率可能受所用免疫抑制方案的影响。
Zotero 插件